| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10036000 | HBV | ENSG00000185010.15 | protein_coding | F8 | No | No | 2157 | P00451 |
| TVIS10031972 | HBV | ENSG00000185010.15 | protein_coding | F8 | No | No | 2157 | P00451 |
| TVIS30010023 | HIV | ENSG00000185010.15 | protein_coding | F8 | No | No | 2157 | P00451 |
| TVIS30000259 | HIV | ENSG00000185010.15 | protein_coding | F8 | No | No | 2157 | P00451 |
| TVIS30073897 | HIV | ENSG00000185010.15 | protein_coding | F8 | No | No | 2157 | P00451 |
| TVIS30073898 | HIV | ENSG00000185010.15 | protein_coding | F8 | No | No | 2157 | P00451 |
| TVIS30073899 | HIV | ENSG00000185010.15 | protein_coding | F8 | No | No | 2157 | P00451 |
| TVIS30073900 | HIV | ENSG00000185010.15 | protein_coding | F8 | No | No | 2157 | P00451 |
| TVIS30073901 | HIV | ENSG00000185010.15 | protein_coding | F8 | No | No | 2157 | P00451 |
| TVIS30073902 | HIV | ENSG00000185010.15 | protein_coding | F8 | No | No | 2157 | P00451 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | F8 |
|---|---|
| DrugBank ID | DB14700 |
| Drug Name | Damoctocog alfa pegol |
| Target ID | BE0000016 |
| UniProt ID | P00451 |
| Regulation Type | binder |
| PubMed IDs | 29765290; 29899890; 27434619; 20194895 |
| Citations | Graf L: Extended Half-Life Factor VIII and Factor IX Preparations. Transfus Med Hemother. 2018 Apr;45(2):86-91. doi: 10.1159/000488060. Epub 2018 Mar 21.@@Morfini M, Gherardini S: Pharmacokinetic-based prediction of real-life dosing of extended half-life clotting factor concentrates on hemophilia. Ther Adv Hematol. 2018 Jun;9(6):149-162. doi: 10.1177/2040620718774258. Epub 2018 Jun 5.@@Klamroth R, Simpson M, von Depka-Prondzinski M, Gill JC, Morfini M, Powell JS, Santagostino E, Davis J, Huth-Kuhne A, Leissinger C, Neumeister P, Bensen-Kennedy D, Feussner A, Limsakun T, Zhou M, Veldman A, St Ledger K, Blackman N, Pabinger I: Comparative pharmacokinetics of rVIII-SingleChain and octocog alfa (Advate((R)) ) in patients with severe haemophilia A. Haemophilia. 2016 Sep;22(5):730-8. doi: 10.1111/hae.12985. Epub 2016 Jul 19.@@Mei B, Pan C, Jiang H, Tjandra H, Strauss J, Chen Y, Liu T, Zhang X, Severs J, Newgren J, Chen J, Gu JM, Subramanyam B, Fournel MA, Pierce GF, Murphy JE: Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood. 2010 Jul 15;116(2):270-9. doi: 10.1182/blood-2009-11-254755. Epub 2010 Mar 1. |
| Groups | Approved; Investigational |
| Direct Classification | Peptides |
| SMILES | |
| Pathways | |
| PharmGKB | |
| ChEMBL |
